Search

Displaying results 5601 - 5610 of 10000 in total
  1. Drug

    Moxazocine

    go.drugbank.com/drugs/DB20517
    Experimental

    Moxazocine is a small molecule drug. The usage of the INN stem '-azocine' in the name indicates that Moxazocine is a narcotic antagonist/agonist related to 6,7-benzomorphan. … Moxazocine has a monoisotopic molecular weight of 287.19 Da.

  2. Drug

    Alferminogene tadenovec

    go.drugbank.com/drugs/DB05306
    Investigational

    Alferminogene tadenovec, Cardium’s lead product candidate, is being developed for the potential treatment of myocardial ischemia that gives rise to angina symptoms associated with coronary heart disease … Alferminogene tadenovec represents a new therapeutic class of biologics designed to promote angiogenesis and thereby improve blood flow following a one-time intracoronary administration from a standard

    Synonyms: Ad5FGF-4
  3. Drug

    Fonadelpar

    go.drugbank.com/drugs/DB16169
    Investigational

    Fonadelpar is under investigation in clinical trial NCT03527212 (A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment of Patients With Dry Eye Disease).

  4. Drug

    Uracil C-13

    go.drugbank.com/drugs/DB16345
    Investigational

    Uracil C-13 is under investigation in clinical trial NCT01677338 (Phase 2 Study to Evaluate the Preliminary Performance of the C13-URA Breath Test Kit in Dyspeptic Subjects).

    Synonyms: Uracil C-13, 2-, Uracil C-13
  5. Drug

    GEM-231

    go.drugbank.com/drugs/DB05798
    Investigational

    GEM231 is a second-generation antisense oligonucleotide targeting the mRNA of the R1alpha regulatory subunit of cAMP dependent protein kinase. … A monoclonal antibody combined with a toxic substance that is used treat certain types of acute myeloid leukemia in older patients and is being studied in the treatment of other types of cancer.

  6. Drug

    Bevirimat

    go.drugbank.com/drugs/DB06581
    Investigational

    Bevirimat targets the protein gag-pol polyprotein. Bevirimat is derived from a betulinic acid-like compound, first isolated from <i>Syzygium claviflorum</i>, a Chinese herb. … It is not currently FDA-approved, but is undergoing clinical trials conducted by the pharmaceutical company Panacos.

  7. Drug

    PN0621

    go.drugbank.com/drugs/DB05218
    Experimental

    PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis. … It is being developed by Peptech.

  8. Drug

    Icotinib

    go.drugbank.com/drugs/DB11737
    Investigational

    . was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC). … Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers
  9. Drug

    Vatalanib

    go.drugbank.com/drugs/DB04879
    Investigational

    Vatalanib is under investigation for the treatment of solid tumors. … Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors.

    Categories: Heterocyclic Compounds, 1-Ring
  10. Drug

    Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)

    go.drugbank.com/drugs/DB16443
    Investigational

    The Recombinant SARS-CoV-2 Vaccine was created by inserting genes of the SARS-CoV-2 spike protein’s receptor-binding domain into a baculovirus expression system[F4738, A226853]. … These promising results have secured a Phase I trial (NCT04530656) to evaluate the safety, efficacy, and immunogenicity in healthy Chinese participants.